Podcasts about qlt

Mark Scherer is the CEO and Founder of Encompass Life.  He has developed the Quantum Leap Technique  (QLT) which produces profound results in all areas of one's life with velocity. What business problem do you solve? In today's episode, Mark Scherer shares his Quantum Leap Technique (QLT) and how it can help business owners overcome stuck patterns and negative emotions, reprogram their subconscious minds, and achieve rapid and profound results in their personal and professional lives. Small Business Answer Man's Shownotes: Gary introduces his guest, Mark Scherer, a mindfulness expert, CEO, and founder of Encompass Life, who shares his unique approach to reprogramming the subconscious mind. Mark discusses the importance of understanding the subconscious mind and its impact on business decisions and overall success. He explains how the subconscious mind can hold us back from achieving success and how it can be reprogrammed to support our goals. Mark shares his Quantum Leap Technique (QLT) and how it can be used to overcome obstacles and achieve rapid and profound results in business and personal life. He discusses the role of emotions in decision-making and how to overcome fear, anxiety, and self-doubt. Mark emphasizes the importance of having a clear vision and setting goals for success. He shares his mission to help business owners overcome stuck patterns and achieve their full potential. Mark encourages listeners to take action and start reprogramming their subconscious minds for success. He provides practical tips and strategies for applying the QLT in daily life. Mark Scherer's Small Business Tip: Reprogram your thinking and overcome limiting beliefs and self-doubt, allowing you to focus on growth and success. Develop a clear and compelling vision for your business, aligning your actions and decisions with your goals and values. Cultivate a resilient mindset, learning to navigate challenges and setbacks with confidence and optimism, rather than getting bogged down in fear or anxiety. Connect with Mark Scherer: Website LinkedIn Instagram Facebook Clarity Navigator Discovery Session – Sign Up HERE Learn more about Gary's Mastermind group at goascend.biz/the-mastermind-solution

En este episodio Mariana nos relata un reciente breakdown emocional y físico que la llevó a retirarse por 15 días para sanar su sistema nervioso. De ahí, tocamos la idea de que el retirarse es algo que no hacemos lo suficiente y que la soledad, el silencio y las pequeñas muertes son fundamentales. Hablamos sobre la exclusión de ideas, personas y filosofías, así como la falta de presencia, como formas de violencia que hemos normalizado y escondido. Hablamos sobre lo que significa la autenticidad en las relaciones y nos cuestionamos la idoneidad de traer hijos a este mundo. ¿Qué significa disolver las cárceles mentales y las creencias cuando tenemos muchas teorías y palabras que nos hacen sentir en control? ¿Cómo invitar la muerte de forma consciente y saber que el silencio es tal vez más elocuente que nuestra teoría?  Lo que nos queda claro es que somos proceso. Y nada más. Mariana Fresnedo es ingeniera industrial y tiene un posgrado en Bioneuroemoción. Es facilitadora del método “The Work” de Byron Katie y Fundadora del método QLT. Es conferencista, hipnoterapeuta, coach de técnicas de respiración y facilitadora de varias técnicas de sanación.

Últimamente en sesiones individuales de QLT™️ llegaron varias mujeres fuertes, independientes y poderosas, que están terminando una relación de pareja, y están atravesando la herida del padre. Así que en este episodio te contaré más sobre esta herida, para ver los patrones que aún se repiten y son indicios de esta herida. Si quieres aprender más a establecer, comunicar y sostener tus límites, este es el nuevo taller de QuantumQuip que puede ayudarte a aprender todo sobre los límites: https://www.quantumquip.com/taller-el-poder-de-mis-limites?utm_source=social&utm_medium=podcast&utm_campaign=taller-el-poder-de-mis-limites&utm_content=podcastEP-La-herida-del-padre Si quieres aprender más te dejo el link al episodio que te mencione, donde te hablo del libro He: https://open.spotify.com/episode/396FovLHA7PlU8RoZX1fa4?si=2050c0fd902045bf

Cuando de relaciones de pareja de trata, lo más fácil del mundo es ignorar la auto traición con la que vivimos y nos habitamos a diario. ¿Qué tantas mentiras te cuentas para encajar en realidades en las que no florece el amor que tienes para ti y para los demás? ¿De qué manera estás cancelando el regalo más hermoso que tienes para el mundo? Pero… ¿Cómo puede uno dejar de vivir en la auto traición?

¿Por qué adoptamos conductas de control? La mente tuvo que aprender que si controlo mi entorno, por ende voy a encontrar seguridad. Pero te tengo malas noticias, las personas y la mayoría de las situaciones son incontrolables. En este episodio, te comparto algunas técnicas para soltar nuestros mecanismos de control. Te dejo el link para que recibas la clase y recibas los 10 compromisos: https://www.quantumquip.com/form-efecto-honey-moon En el episodio mencionó QLT™, aquí te dejo el directorio de facilitadorxs de esta herramienta de reprogramación: https://www.qlt.mx/

A few weeks ago, Christy channeled a new program called Quantum Life Theory. It was brought to us by The White Light. We were excited to jump into this and Joshua began streaming loads of information and we held our first QLT event last month. The event was wonderful and we got so many new insights. Then something new came. There is a process for discovering anyone's Soul purpose. As far as I know, this has never been described before. In this episode, The White Light answers my questions about QLT and this weekend, I was led to this new revelation. We have since channeled a questionnaire that will enable anyone to discover their actual soul's purpose. Send me an email to receive your QLT questionnaire. For more info - theteachingsofjoshua.com Watch the Quantum Life Theory (QLT) Video - here   

The concept of Inversion was revealed to us recently when Christy and I started channeling the Quantum Life Theory program. It's one of the 10 pillars of QLT. An ecstatic life is defined as the transcendence of self. In this episode, Joshua explains the idea of inversion and how it leads to self-transcendence. This is a fascinating topic that I'm sure we'll be hearing more about in the coming weeks. You can watch a video all about Quantum Life Theory on my YouTube channel. Search Gary Bodley on Youtube to watch it. For more info - theteachingsofjoshua.com Please Follow this podcast and leave a review. Here's how you can leave a review on iTunes: Please share this podcast with your friends! New Audio Book - "A Perception of Reality"  

On this episode of The Lead Up Podcast, Mike shares his best Quit Losing Talent tips on how you as a leader can effectively reward and recognize all the different generations that make up your team! This episode aims to inspire leaders to increase their influence and positive impact in how they lead others so grab a pen and a piece of paper to jot down some of the incredible knowledge nuggets dropped in this episode. Mike's top ways to reward and recognize your employees: Provide verbal recognition Offer incentives Provide professional development opportunities/ invest in your employees Celebrate milestones Create a positive workplace culture Provide flexible schedules Provide meaningful feedback Mike also speaks about toxic praise and reminds you that if you lead well, it doesn't matter what generation your employees were born in, all that matters is if they connect with you as an individual. Mike reminds you that he is rewriting and expanding his book, Quit Losing Talent, which you can grab at www.QuitLosingTalent.com, to include more of the QLT framework which teaches leaders how to create a QLT culture within their organizations. Please leave us a review on the platform you listen on and let us know what you want to hear more of to help you in your leadership journey.

En este episodio te cuento cómo nació QLT (tm) y cómo es una herramienta que nos ha transformando tanto. Si estas interesadx en registrarte a la lista de espera para ser parte de la siguiente generación deja tus datos aquí https://www.qlt.mx/qlt-interesados-podcast

Mind over matter. It's a phrase that we've all heard. But, as with many things in life, truth resonates in this simple phrase. One of our favorite husband and wife teams share their journey to be mentally stronger, as individuals and as a couple. Drs. Adam and Mayredlis of Lighthouse Chiropractic share the breaking point in their relationship that brought them to Encompass Life, an organization dedicated to coaching and empowering people to reach their potential through a high level of consciousness via there Quantum Leap technique (QLT). Find out more about Encompass Life and their methods of training the brain to really put mind over matter, providing tools for you to live for today in a more intentional way. In this part of our conversation we discuss the essence of consciousness: what is it really? And why it's important to harness your brainpower to create a more holistic version of you. Lighthouse Chiropractic: https://www.getlhc.com/ https://www.instagram.com/lighthousechiropracticnocatee/ Encompass Life: https://www.encompasslife.com/ https://www.instagram.com/quantumleaptechnique/ Find More Nada: Website: https://mamaknowsnada.com/ Instagram: https://www.instagram.com/mama.knows.nada/ Facebook: https://www.facebook.com/mamaknowsnada/ Music: "Vacaciones" by Mike Leite Kindly note, opinions and statements made by guests on the Mama Knows Nada Podcast do not necessarily reflect the values and opinions held by Mama Knows Nada. Guests are sharing their own unique perspectives and experiences. Always consult your healthcare provider for options appropriate to your personal circumstances.

コーチングを習慣化して、日常で息をするようにできれば コミュニケーション力が爆上がりして、QLTが爆上がりします❣️ 私は息子のサッカーチームでも実験してみたんですが、明らかにチームの空気が変わりました

Lance Hardwick and his trusty sidekick Dick Reardon help a beautiful and self-reliant reporter solve a series of murders that were apparently committed by Clowns, but they soon discover that the Roswell Crash may hold vital clues! And the mysterious Government Agency, The QLT-7, make their appearance for the first time! Make sure to listen to the "After-Credits" scene - if you DARE! Learn more about your ad choices. Visit megaphone.fm/adchoices

Lance Hardwick and his trusty sidekick Dick Reardon help a beautiful and self-reliant reporter solve a series of murders that were apparently committed by Clowns, but they soon discover that the Roswell Crash may hold vital clues! And the mysterious Government Agency, The QLT-7, make their appearance for the first time! Make sure to listen to the "After-Credits" scene - if you DARE! Learn more about your ad choices. Visit megaphone.fm/adchoices

This show is for anyone who has jumped through lots of hoops to get certified and for those who are working hard to put together the required documentation to obtain your certification – and addresses the question many have been wondering – which is Now what? We also send our congratulations to Victoria Brannigan, CEO of The Queen's Lovely Things - aka "QLT." --- Send in a voice message: https://anchor.fm/boomnow/message

David Main is President and Chief Executive Officer of Notch Therapeutics. Previously, as Chairman and CEO of Aquinox Pharmaceuticals, a company he founded in 2004, Mr. Main oversaw the advancement of the company’s lead product from target validation through Phase 3 clinical trials. He also led the transition of Aquinox from a private company to a NASDAQ-listed public company with approximately $300 million raised in equity capital and then completed the successful merger of Aquinox with Neoleukin Therapeutics. Prior to his leadership of Aquinox, David served as President and CEO of INEX Pharmaceuticals and as a Vice President of QLT. He formerly served as the Chair of LifeSciences BC (formerly BC Biotech), BIOTECanada, and Accel-Rx as well as a Director of BIO.org. David began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. He holds a B.Sc. (Pharmacy) and an MBA from the University of British Columbia (UBC).

Get in everyone, 'cause today we are going to court, and the Brits are ready to spill the hot cuppa. I've got to say, I'm super excited for our fourth episode where we gonna talk about queerness in a very unusual place when we think about the LGBTQ+ community, which is the legal setting. One of the most prominent conversations we're having in recent years is how we can promote diversity of sexes, races and beliefs in different scenarios. Created by Liv Reily and Owen Hussey, Queer Lawyers of Tomorrow, is an organisation aiming to promote, assist and propel LGBTQ+ individuals in the legal career via a platform where these minorities can feel welcomed to be who they are and also continue in their legal profession. With a networking community, events, application support, shared opportunities and an ally network, Queer Lawyers of Tomorrow hope to promote an ever-expanding openness in the legal work field. One of our guests today is Liv Reily. Liv has just graduated in Law at the University of Exeter and wants to work with entertainment law. As I mentioned before, she's also one of the founders of Queer Lawyers of Tomorrow. We are also receiving another guest today, Callum Ward. Callum is a final year student of Law at the University of Lincoln and is also one of the admin assistants of QLT as well. He wants to work with family law in the future. With them, we gonna address Liv's experience being a member of the LGBTQ+ community whilst being a lawyer, and in contrast, Callum's experience of not being a member of LGBTQ+ community but how by being an ally has helped him and what's the necessity of allyship to social movements nowadays. Needless to say, our talk today is extremely important, informative and inspiring. One of the things that caught my attention the most is how the members of Queer Lawyers of Tomorrow, decided to create this astounding platform after many frustrations in the work field because of their sexual identity. An so forth set themselves to build a space where they can be accepted and welcomed. Showing that everyone must be invited to the legal party. So better open your vacancies, or, we are suing (finally reached my dream to say it out loud on the internet). Happy belated pride everyone. Matt xxx

What does the Canadian Biotech ecosystem look like?  What are companies doing to help us stay healthy? Help feed ourselves? And power our planes, trains and automobiles? And how can they achieve this in a sustainable way? What network effects are there in the biotech landscape? On this episode of Market Hunt, we chat with Andrew Casey, President of BIOTECanada. Guest Bio:Andrew CaseyIn his role as President & CEO of BIOTECanada Andrew is responsible for the day-to-day operations of the Association.  In this capacity, he is the primary spokesperson for Canada’s biotech industry communicating on the industry’s behalf with government, regulators, international bodies, media and the Canadian public. He also ensures BIOTECanada plays a central role in partnership with Government in the development of policy relating to Canada’s biotech sector and the member companies of BIOTECanada.

We sit down with Halifax fullback Quentin Laulu-Togaga'e - better known as QLT. They go through his career and life, from Auckland to Brisbane and then northern England, and discuss his experiences playing alongside Billy Slater and Cooper Cronk in the Queensland Cup, winning grand finals with Sheffield and playing for Toronto. They also cover his brief Super League stint with Castleford, his return to Halifax, representing Samoa and a lot more.

We sit down with Halifax fullback Quentin Laulu-Togaga'e - better known as QLT. They go through his career and life, from Auckland to Brisbane and then northern England, and discuss his experiences playing alongside Billy Slater and Cooper Cronk in the Queensland Cup, winning grand finals with Sheffield and playing for Toronto. They also cover his brief Super League stint with Castleford, his return to Halifax, representing Samoa and a lot more.

This episode we follow up our conversation about the Wealth. We talk Wealth Chasm, the way we can position ourselves, and so much more. Digit: digit.co/r/qLT_2?an Acorn: Start investing with Acorns today! Get $5 when you use my invite link: https://acorns.com/invite/BTQFCT

Gene DeJuan, Jr., MD, Founder & Vice-Chairman, ForSight Labs Renowned retinal surgeon, inventor and entrepreneur Dr. Eugene de Juan, Jr., serves as Vice-Chairman of ForSight Labs, where he participates as an active inventor and advisor in early-stage ophthalmic device opportunities. Dr. de Juan, Jr., splits his time between ForSight Labs and UCSF. He holds the “Jean Kelly Stock Distinguished Chair” in Ophthalmology. UCSF recruited Dr. de Juan for this special role to augment translation of the many ideas being developed within the academic center. He continues to see patients, operate and teach at UCSF. Dr. de Juan, Jr., has participated in the development of a number of ophthalmology's most exciting new technologies with over 100 products and the founding of nine venture funded companies including Second Sight, InnoRx, NeoVista, and Retina Labs, in addition to ForSight Labs' first five “VISION” companies: Transcend Medical, Inc., founded in 2005; VISION2 (acquired by QLT, Inc. in 2007); Nexis Vision, Inc. (formerly ForSight VISION3, Inc.), founded in 2007; ForSight VISION4, Inc., founded in 2009; and ForSight VISION5, Inc., founded in 2010. Prior to moving to San Francisco, Dr. de Juan, Jr., was a professor of ophthalmology at the University of Southern California and CEO of the Doheny Eye Institute, focusing on innovative techniques for treating blinding retinal disorders through retinal transplantation, macular translocation, robotic surgery, retinal implants, and other new procedures, medicines and instruments. Prior to these positions, Dr. de Juan served at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, where he was Co-Director of Vitreoretinal Service, Director of the Microsurgery Advanced Design Laboratory (MADLAB) and Joseph E. Green Professor of Ophthalmology. From 1983 to 1992, he was a member of the medical staff of the Duke University Eye Center, holding joint teaching appointments with the departments of ophthalmology and cell biology. He is a passionate supporter of ophthalmic education and development and has recently helped established a chair for Ophthalmic Education at Johns Hopkins University. Dr. de Juan completed his medical degree and internship training at the University of South Alabama College of Medicine. He served an internship at University of South Alabama Medical Center followed by a residency at the Wilmer Ophthalmological Institute in Baltimore, MD, and a fellowship in vitreoretinal surgery at Duke University. He holds patents on over sixty medical devices and is responsible for more than 250 academic publications.

Canadians invent many things that go on to be globally significant. Drugs or pharmaceuticals is an area of research that we do very well in, especially when it comes to developing cures and treatments for a wide range of health issues.   While we do a good job conceiving of treatments and doing the research, we don’t do a good job of bringing those products to the market. By the time the research has finished, ownership of the intellectual property frequently leaves Canada and moves to its new home in Europe or the United States.   It’s a shame because Canada makes up just point five per cent of the global population, yet we produce over 5% of the world’s research in drug development. We’ve figured out the idea and research part well; what we have trouble with is commercializing our discoveries once the human proof of concept stage has been reached.   Canada is the only advanced pharma market in the world that does not have a billion dollar company to anchor the pharmaceutical industry.  We’ve had them only to see them go away. At one time we had QLT in Vancouver, which is an example of our intellectual property being acquired by a larger global player that takes the company offshore.   The result is a loss to ongoing research and to the Canadian economy. How then do we change that? Enter the Centre for Drug Research and Development, a joint effort between Simon Fraser University, UBC and the BC Cancer Agency – an initiative that the Federal Government recognized as invaluable and provided funding to expand the reach of the CDRD across the country.   We invited Gordon McCauley of the CDRD to join us for a Conversation That Matters about nurturing, fostering, retaining and commercializing our world-class ideas, talent and research in Canada.       Simon Fraser University’s Centre for Dialogue presents Conversations That Matter. Join veteran Broadcaster Stuart McNish each week for an important and engaging Conversation about the issues shaping our future.   Please become a Patreon subscriber and support the production of this program, with a $1 pledge https://goo.gl/ypXyDs

Bellus Health is left reeling as its lead drug Kiacta fails its Phase 3 clinical study, Vancouver based QLT inks a merger deal with Aegerion Pharmaceuticals and looks to a fresh new start, and Biotechnology Focus relaunches its Hot Button Issue Survey. We have this and more on this weeks show! Show Notes: We kick things off this week with some bad news on both the business and the clinical trial front with BELLUS Health the rare disease drug development firm reporting top line results from its Phase 3 study of KIACTA™ (eprodisate) as a treatment of AA amyloidosis. The disease is characterized by secondary to severe chronic inflammation or infection leading to the formation and deposition of amyloid fibrils in organs, often resulting in end-stage renal disease and death. Currently there are no therapies available that target the disease directly. According to company CEO Roberto Bellini, KIACTA™ failed to meet its primary efficacy endpoint in slowing renal function decline. The news, announced on June 20, was somewhat surprising to both the company and its investors. Shares for the company on the TSE under the trade symbol BLU plummeted, going from $2.42 on June 17, to around $0.39 on the day of the announcement, holding at .40 cents today. Many investors had rallied to the company over the past year due to the drug being in later stages of clinical trial development. Moreover, the science seemed sound as in earlier studies, KIACTA™ was shown to significantly delay the disease.  In both earlier studies and even in the failed trial, it was found to be safe and well tolerated over treatment periods of greater than four years. The confirmatory Phase 3 study of KIACTA™ was a global study across more than 70 sites in more than 25 countries that randomized 261 patients to receive either 800mg dose of KIACTA™ twice daily or placebo. The  study was an event driven study that lasted five years meeting its completion target of 120 patient events linked to the deterioration of kidney function in January 2016. The company added that further analysis of the data is ongoing, and a more detailed data set of the KIACTA™ Phase 3 study will be presented July 6 at the XV International Symposium . Roberto Bellini, president and CEO of the company adds that while Bellus is disappointed that the Phase 3 study did not meet the primary efficacy endpoint, the full data set will be assessed to determine the best path forward. The company says in the aftermath of the failed trial, it will continue working on a number of other projects in its portfolio,  including its study of KIACTA™ as a treatment for sarcoidosis (set to enter Phase 2 trials), clinical development of Shigamab™ as a treatment for STEC-related Hemolytic Uremic Syndrome (sHUS), and the company’s research-stage project for AL amyloidosis. We go from negative news to the more positive, as QLT Inc., once upon a time Canada’s hottest biotech company, and a company long-entrenched as a in the BC- biotech community inking a strategic merger agreement with Cambridge-based Aegerion Pharmaceuticals, Inc. The proposed deal has been approved by the board of directors of both companies, and is expected to close late in the third quarter or during the fourth quarter of 2016. Upon closing, QLT says it plans to change its name to Novelion Therapeutics Inc. adding that its common shares will trade on the NASDAQ Global Select Market and the Toronto Stock Exchange. QLT’s current market cap is approximately $110 million (CDN) and Aegerion has a market cap of approximately $70 million (CDN) giving the new combined company a market value of approximately $180 million. This isn’t QLT’s first attempt to merge with another company, having been thwarted in the past in prior merger arrangements with Endo International, Auxilium Pharmaceuticals and InSite Vision. The planned merger with Endo International was terminated in October 2014, and likewise, Auxilium had also been carrying out plans to merge with QLT but chose instead to be bought by the aforementioned Endo International in a separate deal valued at $2.6 billion. Likewise, last year, QLT and InSite announced a merger, but that deal fell through after InSite changed its mind and accepted a higher merger offer from Sun Pharmaceutical Industries. This time QLT won’t be left at the alter so to speak, and likewise both companies under the Novelion Therapeutics Inc. banner will get a much needed rebrand and fresh start. The new company will also have quite a diversified portfolio consisting of Aegerion’s two commercially branded products, Juxtapid® (lomitapide) capsules and Myalept® (metreleptin), and QLT’s QLT091001 (Zuretinol Acetate or Zuretinol), a Phase 3-ready Ultra-Orphan Fast Track and Orphan Drug designated asset being developed for the treatment of Inherited Retinal Disease caused by underlying mutations in RPE65 or LRAT genes (IRD), which indication comprises Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). Aegerion’s CEO, Mary Szela, will serve as CEO of Novelion following the close of the transaction. Additionally, an investor syndicate comprised of both new investors and existing shareholders of both companies has  committed to invest via a private placement approximately $22 million in QLT. The investment will be funded prior to the transaction close and is expected to provide Novelion with additional capital to support future operations and the potential opportunity for targeted business development initiatives. In futher business news, TVM Life Science Ventures VII a venture capital fund domiciled in Montréal, Québec, has closed the fund’s eleventh investment, establishing Mediti Pharma Inc., a company based in Montréal, Québec. The new company is developing a Phase 2 ready compound, MP-101, originally discovered by Eli Lilly and Company for the treatment of Alzheimer’s disease (AD) psychosis. The behavioral symptoms associated with AD psychosis, include hallucinations, delusions and aggression. The company is managed by CEO Dr. Ivan Shaw, formerly with Merck Frosst, Aptalis and Actavis and neurobiologist and experienced drug developer and CFO Mark Cipriano, a Boston-based highly experienced and networked executive. As for the fund itself, and its initial association with the drug, it comes about as part of a unique arrangement between TVM Capital Life Science and numerous limited partners, which includes Eli Lilly and Company.  The goal of the fund is to finance and access innovation while managing risk and sharing reward. Staying in Montreal, on the clinical trial front Montreal InVivo , the city’s economic development organization with a focus on life sciences and health technologies (LSHT) sector. is partnering with Canadian Clinical Trails Coordinating Centre(CCTCC) to enhance Canada's clinical research capabilities. The partnership will result in the addition of Quebec clinical trial investigators "data from Montreal Goes Clinic to the Canadian ClinicalTrials Asset Map (CCTAM) and real-time updates down the line. The Montreal Goes Clinic itself is an initiative by Greater Montreal's life sciences"; cluster that aims to make the region a world-class centre of expertise in early stage clinical trials.  The goal of this initiative is to improve Greater Montreal's business environment by helping pharmaceutical, biotech, contract research organizations (CRO's) and medical device companies perform high quality clinical trials and run clinical proofs-of- concept, thus  increasing patient access to new treatments and improving medical practices by allowing clinicians to work with technologies of tomorrow and the best equipment. Frank Béraud, CEO of Montréal InVivo adds that the portal will create more visibility for Quebec's researchers and investigators throughout Canada, and will also showcase the province's capabilities in clinical research. Dr. Shurjeel Choudhri, senior vice president and head, Medical and Scientific Affairs Bayer Inc. and the current Chair of the CCTCC Executive Committee adds that the CCTAM is a great example of the collaboration of multiple stakeholders from across Canada, including representatives from the Federal and Provincial governments, industry, the Canadian Institutes of Health Research and HealthCareCAN. He calls the addition of clinical investigator data from Montreal Goes Clinic an important step towards making the CCTAM a truly comprehensive inventory of Canada's clinical research assets. If you could have a face-to- face conversation with government to discuss the life science industry, both the good and the bad what would you say? A number of years ago Biotechnology Focus used to run a special Hot Button Issue survey which gave our readers the opportunity to engage with government to get their concerns before the right people and have their voices heard. Well, with the Justin Trudeau government coming up to its ninth month in office, we thought the timing was right to do it all again. The survey kicked off yesterday and will run to July 15, 2016. Similar to our past “Hot Button” issue surveys, we want your feedback on such things as regulatory policy including reimbursement of new technologies, funding challenges, intellectual property protection, the state of the industry and much more. This survey is open to everyone in the industry, from the business sector, to research institutions, and at all levels, essentially, if your field is biotech, bioscience or life science in general we want to hear from you. This already is vibrant industry, with strong representation at major research and knowledge translation institutions, a large base of Canadian biotech SMEs and MMEs, and we’re home to many of the world's largest and leading pharmaceutical companies. Moreover, the timing for this survey couldn’t be better as the Federal government as mentioned in last week’s podcast has just launched the “Innovation Agenda”, an action plan to both redesign and redefine how we as a nation support innovation and growth. They have embarked on this Innovation Agenda in partnership and coordination with the private sector; provinces, territories and municipalities; universities and colleges; and the not for-profit sector and they have also already taken the first steps in this plan already with Budget 2016, providing support for health research, genomics, regenerative medicine, brain research and drug development and committed $800 million to support innovation networks and clusters. So there’s obviously lots that government is doing right to make Canada a friendly environment for our industry, but can we do more? Canada’s Minister of Innovation, Science and Economic Development Navdeep Bains has asked us all to step up and voice our opinions, to help further shape the future of Canada’s knowledge based economy. And our Hot Button Issue survey is your chance to do that! Your answers will be featured in a special high profile issue that will be poly-bagged with our sister publication Canadian Government Executive magazine and sent to Deputy Ministers, Assistant Deputy Ministers, Cabinet, Directors and Generals, working in Health Canada, Industry Canada, Agriculture & Agri-Food, Foreign Affairs & Internationals trade, the Privy Council as well as other public sector executives in federal and provincial departments. So here is your chance to help influence the Innovation Agenda. And remember, by taking only a couple of minutes to complete our survey, you’re helping us grow Canada’s knowledge-based economy, one answer at a time. You can access the survey by clicking the link below this podcast. That wraps up this weeks show, you can find us online at www.biotechnologyfocus.ca. Likewise, we’re always looking for feedback, story ideas and suggestions so we’d love to hear from you. Simply reach out to us on twitter: @BiotechFocus , email at biotechnology_focus@promotive.net For all of us here at Biotechnology Focus, thank you for listening.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord: